



SCIENCE @ DIRECT

Register or Login: Password:  [Home](#)[Search](#)[Journals](#)[Abstract Databases](#)[Books](#)[Reference Works](#)[My Profile](#)[Alerts](#)Quick Search:  within [All Full-text Sources](#)  [? Search Tips](#)[← results list](#)[← previous](#)

10 of 40

[next →](#)**Drug And Alcohol Dependence**

Volume 65, Issue 2, January 1, 2002, Pages 115-127

ISSN: 0376-8716

MEDLINE®

**Trauma and substance cue reactivity in individuals with comorbid posttraumatic stress disorder and cocaine or alcohol dependence****✶Coffey, ✶ Scott F; Saladin, Michael E; Drobles, David J; Brady, Kathleen T; Dansky, Bonnie S; Kilpatrick, Dean G**Department of Psychiatry, State University of New York at Buffalo, Buffalo General Hospital, 80 Goodrich Street, Buffalo, NY 14203, USA; e-mail [scoffey@acsu.buffalo.edu](mailto:scoffey@acsu.buffalo.edu)**This Document**[▶ Abstract-MEDLINE](#)**ScienceDirect Links**[· Abstract](#)**Actions**

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

**Abstract**

Although the high comorbidity of posttraumatic stress disorder (PTSD) and substance use disorders has been firmly established, no laboratory-based studies have been conducted to examine relationships between the two disorders. Using cue reactivity methodology, this study examined the impact of personalized ✶trauma✶-image cues and in vivo drug cues on drug-related responding (e.g. craving) in individuals with PTSD and either crack cocaine (CD) or alcohol dependence (AD). CD and AD groups displayed reactivity to both ✶trauma✶ and drug cues when compared to neutral cues, including increased craving. However, the AD group was more reactive than the CD group to both classes of cues. The CD participants were more reactive to ✶trauma✶-image cues if drug-related material was included in the image while the AD participants were reactive to the ✶trauma✶ cues regardless of drug-related content. It is hypothesized that PTSD-related negative emotion may play a relatively more important role in the maintenance of AD when compared to CD. Evidence that substance dependent individuals with PTSD report increased substance craving in response to ✶trauma✶ memories is offered as a potential contributing factor in the poorer substance abuse treatment outcomes previously documented in this comorbid population. [Journal Article; In English; Ireland]

**Citation Subset Indicators:** Index Medicus**Grant Information:** Grant ID: DA 10595, Acronym: DA, Agency: NIDA;

Grant ID: T32 DA07288, Acronym: DA, Agency: NIDA

**MeSH Terms:** Adult; \* Affect; Alcoholism, diagnosis (DI), \* epidemiology (EP); Arousal, physiology (PH); Cocaine-Related Disorders, diagnosis (DI), \* epidemiology (EP); Comorbidity; \* Cues; Female; Human; Imagination; Impulse Control Disorders, diagnosis (DI), epidemiology (EP); Male; Psychiatric Status Rating Scales; Severity of Illness Index; Stress Disorders, Post-Traumatic, diagnosis (DI), \* psychology (PX); Support, U.S. Gov't, P.H.S.; Temperance

---

## Drug And Alcohol Dependence

Volume 65, Issue 2 , January 1, 2002, Pages 115-127

ISSN: 0376-8716

### This Document

► **Abstract-MEDLINE**

### ScienceDirect Links

• [Abstract](#)

### Actions

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

◀ results list

◀ previous

10 of 40

next ▶

[Home](#)

[Search](#)

[Journals](#)

[Abstract Databases](#)

[Books](#)

[Reference Works](#)

[My Profile](#)

[Alerts](#)

[Feedback](#) | [Terms & Conditions](#) | [Privacy Policy](#)

Copyright © 2004 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.

[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L3: Entry 16 of 19

File: USPT

Oct 16, 2001

DOCUMENT-IDENTIFIER: US 6303157 B1

TITLE: Extracts of kava-kavaAbstract Text (1):

This invention relates to a kava-kava lactone-containing product. Also disclosed is a method of preparing such a kava-kava lactone-containing product by extracting kava-kava lactones from crude kava-kava extracts with a solubilizing agent.

Assignee Name (1):Kava Pharmaceuticals, Inc.Assignee Group (1):Kava Pharmaceuticals, Inc. DE 02Brief Summary Text (2):

The plant kava-kava (piper methysticum Forst. Piperaceae) is native to Polynesia. An intoxicating beverage made from its crushed roots has been used in ceremonies since ancient times.

Brief Summary Text (3):

Kava-kava has been found to have significant analgesic and anesthetic effects via non-opiate pathways. It also can be used as phytotranquilizer to reduce nervousness and overexcitement. However, kava-kava's most popular application is as a natural anxiolytic and has compared favorably to a number prescription medications such as benzodiazepines. Kava-kava's pharmacological activity has been attributed to lactones present in the plant roots.

Brief Summary Text (4):

Several kava-kava products are available, such as kava-kava-based beverages, kava-kava ethanol extract solutions, kava-kava emulsions with glycerin and coconuts oil dispersed in water, and kava-kava extract tablets. Unfortunately, the active lactones in kava-kava-based products have low bioavailability since the lactones themselves are practically insoluble in water. For example, the maximum solubility of kawain at 21.degree. C. is about 2.2 mg/100 ml water. Accordingly, high doses of kava-kava-based products or the active lactones are required to obtain therapeutic effects.

Brief Summary Text (6):

In one aspect, the invention features a method of obtaining a kava-kava lactone-containing product by heating pulverized kava roots in an aqueous solution which contains a cyclodextrin-based solubilizing agent to extract kava-kava lactones from the pulverized kava-kava roots.

Brief Summary Text (7):

In another aspect, the kava-kava lactone-containing product in dried form includes greater than about 50 parts by weight (e.g., about 50 to about 99 parts by weight) of one or more of the active kava-kava lactones and has a solubility of at least about 0.05 mg/ml (e.g., about 0.05 mg/ml to about 25 mg/ml), preferably greater than about 0.1 mg/ml, and most preferably greater than about 1 mg/ml in water at about 25.degree. C.

Brief Summary Text (9):

In another aspect, the invention features a method of removing flavokawains from a crude kava-kava lactone-containing preparation. The method includes heating the crude kava-kava lactone-containing preparation in an aqueous solution which contains a cyclodextrin-based solubilizing agent to solubilize kava-kava lactones and thereby produce an aqueous kava-kava lactone-containing solution; and removing flavokawains from the solution, such as by filtering. Crude kava-kava lactone-containing preparations, typically, are produced by extracting pulverized kava-kava root with an organic solvent and are commercially available as kava-kava extracts.

Brief Summary Text (10):

In yet another aspect, the invention features a solubilized kava-kava root extract in aqueous form including active kava-kava lactones in a concentration greater than 0.05, preferably greater than about 0.1, and most preferably greater than about 1 weight percent of the extract, and flavokawains in a concentration of less than about 0.3 weight percent of the extract.

Brief Summary Text (11):

In still another aspect, the invention features a solubilized kava-kava root extract in dried form including active kava-kava lactones in a concentration greater than about 50 weight percent of the extract, and flavokawains in a concentration of less than about 0.3 weight percent of extract.

Brief Summary Text (12):

The kava-kava lactone-containing product (i.e., kava-kava root extract) of this invention exhibits desirable composition and performance. It has a high content of kava-kava lactones and a low content of flavokawains, and increased bioavailability and skin permeability of kava-kava lactones when used as an ingredient in a food, pharmaceutical, or cosmetic product.

Drawing Description Text (2):

FIG. 1 shows the HPLC spectrum recorded at 254 nm of the major components in a kava-kava lactone-containing product of this invention.

Detailed Description Text (2):

The present invention relates to a kava-kava lactone-containing product which contains one or more active kava-kava lactones complexed with cyclodextrin-based solubilizing agents. The water solubility of active kava-kava lactones complexed with cyclodextrin can be increased by a factor of about 20 relative to the water solubility of the active kava-kava lactones not complexed with the cyclodextrin-based solubilizing agent. The increased water solubility improves the physiological absorption of active kava-kava lactones into the body.

Detailed Description Text (3):

The active lactones in kava-kava are kawain, dihydrokawain, methysticin, dihydromethysticin, yangonin and desmethoxyyangonin, i.e. 6-substituted 4-methoxypryones of the formulae: ##STR1##

Detailed Description Text (5):

The present invention also relates to a kava-kava lactone-containing product which has reduced amounts of flavokawains of the formula: ##STR2##

Detailed Description Text (6):

Flavokawains are flavone derivatives of the kava-kava active lactone kawain, shown above, and induce undesirable secondary effects such as a scaly skin rash called "Kava dermatopathy" when crude kava-kava lactone-containing preparations (e.g., crude kava-kava extracts) are consumed for long-terms or in large amounts. Crude kava-kava lactone-containing preparations, typically, are produced by extracting kava-kava lactones from pulverized kava-kava root with an organic solvent, such as

ethanol (ETOH), which also co-extracts flavokawains along with the desired lactones. The kava-kava lactone-containing product of this invention can be taken orally or applied to the skin. In dried form (e.g., a dry solubilized kava-kava root extract), it includes greater than about 50 parts by weight of one or more of the kava-kava lactones and less than about 0.3 weight percent of flavokawains, and has a solubility greater than about 0.05 mg/ml preferably greater than about 0.1 mg/ml, and most preferably greater than about 1 mg/ml in water at about 25.degree. C. The kava-kava lactone-containing product, in aqueous form (e.g., an aqueous solubilized kava-kava root extract), includes less than about 0.3 weight percent of flavokawains and kava-kava lactones in a concentration greater than about 0.05, preferably greater than about 0.1, and most preferably greater than about 1 weight percent of the extract. Unexpectedly the method of this invention enables one to extract directly the kava-kava lactones from kava-kava roots without using organic solvents by complexing the kava-kava lactones with a solubilizing agent, e.g., a cyclodextrin-based solubilizing agent.

Detailed Description Text (10):

The method of preparing a kava-kava lactone-containing product includes mixing between about 1 and about 20 parts by weight of a crude kava-kava extract or pulverized kava-kava root with about 100 parts by weight of a solution heated to between about 30.degree. C. and about 70.degree. C. of water containing about 0.01 to about 25 percent by weight, and preferably about 0.1 to about 15 percent by weight of the cyclodextrin-based solubilizing agent relative to the total weight of the aqueous solution. The resulting mixture is heated to about 50.degree. C. to about 90.degree. C. and stirred for about 1 to about 10 minutes. While stirring, the mixture is cooled to about 30.degree. C. to about 50.degree. C. for between about 1 and about 10 minutes. The supernatant contains water-soluble complexes of active kava-kava lactones and cyclodextrin-based solubilizing agents.

Detailed Description Text (11):

Unexpectedly, cyclodextrin-based solubilizing agents have relatively weak affinity for forming a water-soluble complex with flavokawains as compared to kava-kava lactones. As a result most of the flavokawains in the kava-kava crude extract or pulverized kava-kava root are not solubilized into the supernatant. Residual amounts of flavokawains in the supernatant, e.g., about 3% to about 0.5%, give rise to a yellow color of the supernatant and can be removed by microfiltering the supernatant. The microfiltered supernatant is colorless and substantially flavokawain-free. Any microfilter having a pore size sufficient to remove residual flavokawain (e.g., 1 .mu.m) can be used. In alternative embodiments, residual amounts of flavokawains in the supernatant can be removed by cold precipitation or solvent distribution.

Detailed Description Text (12):

The kava-kava lactone-containing product of this invention can be produced by a batch method or a flow method, i.e., a continuous extraction and filtration process. Typically, flow processes are used to help maintain reasonable manufacturing costs. The kava-kava lactone-containing product in aqueous form can be dried, (e.g., under vacuum) to produce a dried product. The kava-kava lactone-containing product, either in dried or aqueous form, can be incorporated into an edible composition, pharmaceutical composition, a cosmetic product, or a skin care product. The edible composition can be a solid, a paste, or a liquid food product, such as water, milk, tea, coffee, soft drinks, juices, beer, seasonings, cereals, cookies, chewing gum, chocolate, or soups.

Detailed Description Text (15):

50 g of a crude kava-kava extract containing about 7.5 g of kava-kava lactones and about 3 weight percent flavokawains. (i.e., alcohol free KAVA-KAVA root suspension manufactured by Nature Answer Inc., Hauppauge, N.Y.) was added to 3 liters of hot water containing 200 g of hydroxypropyl beta cyclodextrin (Trappsol manufactured by Cyclodextrin Development Inc, Gainesville, Fla.) at 70.degree. C. The mixture was

stirred at 90.degree. C. for 10 minutes and then at 50.degree. C. for an additional 10 minutes. The supernatant was filtered through a 1 .mu.m-pore size microfilter to yield 3.3 liters of a visibly colorless and clear water-soluble kava-kava lactone-containing solution. The kava-kava lactone content of the solution was about 1.6 mg/ml. The concentration of flavokawains was less than about 0.3 weight percent.

Detailed Description Text (17):

50 g of a crude kava-kava extract containing about 7.5 g of kava-kava lactones extracted with EtOH and about 3 weight percent flavokawains ( i.e., KAVA-KAVA Root GBE ethanol solution manufactured by GAIA Herbs Inc, Brevard, N.C.) was added to 3 liters of hot water containing 300 g of hydroxypropyl beta cyclodextrin (Encapsin HPB manufactured by American Maize-Products Company, Hammond, Id.) at 70.degree. C. The mixture was stirred at 90.degree. C. for 10 minutes. Residual EtOH was removed from the mixture by evaporation under vacuum at 30.degree. C. The supernatant was filtered through a 1 .mu.m-pore size microfilter to yield 3.2 liters of a visibly colorless and clear water-soluble (alcohol-free) kava-kava lactone-containing solution. The kava-kava lactone content of the solution was about 2.0 mg/ml. The concentration of flavokawains was less than about 0.3 weight percent.

Detailed Description Text (19):

50 g of a crude kava-kava extract containing about 7.5 g of kava-kava lactones and about 3 weight percent flavokawains (i.e., KAVA-KAVA Root GBE ethanol solution manufactured by GAIA Herbs Inc, Brevard, N.C.) was added to 3 liters of hot water containing 20 g of .beta.-cyclodextrin (C\*Cavitron 82800, food grade, manufactured by Cerester USA Inc in Hammon, Ind. The mixture was stirred at 90.degree. C. for 10 minutes and then at 50.degree. C. for an additional 10 minutes. The supernatant was filtered through a 1 .mu.m-pore size microfilter to yield 3.0 liters of a visibly colorless and clear water-soluble kava-kava lactone-containing solution. The kava-kava lactone content of the solution was about 0.25 mg/ml. The concentration of flavokawains was less than about 0.3 weight percent.

Detailed Description Text (21):

50 g of a crude kava-kava extract containing about 5 g of kava-kava lactones extracted with EtOH and about 3 weight percent flavokawains (i.e., KAVA-KAVA Root GBE ethanol solution manufactured by GAIA Herbs Inc, Brevard, N.C.) was added to 3 liters of hot water containing 20 g of cyclodextrin and 150 g of hydroxypropyl beta cyclodextrin at 70.degree. C. The mixture was stirred at 90.degree. C. for 10 minutes and then at 50.degree. C. for an additional 10 minutes. The supernatant was filtered through a 1 .mu.m-pore size microfilter to yield 2.8 liters a visibly colorless and clear water-soluble kava-kava lactone-containing solution. The kava-kava lactone content of the solution was about 1.2 mg/ml. The concentration of flavokawains was less than about 0.3 weight percent.

Detailed Description Text (23):

A crude kava-kava extract containing 75 mg kava-kava lactones per 1 ml ethanol and about 3 weight percent flavokawains (KAVA-KAVA Root GBE manufactured by GAIA Herbs Inc, Brevard, N.C.) was used to prepare a reference standard for high-pressure liquid chromatography (HPLC) measurements. More specifically, 1 ml of the standardized kava-kava extract was added to 9 ml of water containing 1 g of hydroxypropyl beta cyclodextrin (USP grade) at 50.degree. C. The mixture was stirred for 5 minutes to yield a standardized kava-kava extract solution (yellowish). An HPLC sample was prepared by diluting it with 5.times. of 80% EtOH. The concentration of flavokawains in the sample was about 3 weight percent.

Detailed Description Text (24):

HPLC spectra were recorded on a HP 1050 instrument (Hewlet Packard) using a C18-reverse phase column 150 mm.times.4.6 mm, Symmetry Shield RP18 available from (Waters) by a gradient elution method, i.e., 1 ml/min for 20 minutes with 20%-95% aqueous acetonitrile and 0.1% trifluoroacetic acid at 30.degree. C. The HPLC detector was set at either 254 nm or 330 nm. FIG. 1 shows the HPLC spectrum of the

standardized kava-kava extract solution recorded by monitoring the absorption at 254 nm as a function of time. FIG. 2 shows a HPLC spectrum of the standardized kava-kava extract solution recorded by monitoring the absorption at 330 nm as a function of time. The six kava-kava lactones appear in the HPLC spectra of FIGS. 1 and 2 as overlapping peaks (FIG. 3) Note that the intensity of each absorbance is not directly related to the relative amounts of kava lactones in the standardized Kava extract because each lactone has a different absorption maxima ( $\lambda_{max}$ ) value and extinction coefficient.

Detailed Description Text (26):

Flavokawains have a maximum absorption around about 340 nm and are responsible for the yellow color of the standardized kava-kava extract solution. The flavokawian's (i.e., the yellowish color) in the HPLC sample of Example 5 were removed from the solution by filtering it with through a 0.45  $\mu$ m microfilter. The concentration of flavokawains in the filtered HPLC sample was less than about 0.3 weight percent.

Detailed Description Text (28):

200 g of pulverized dry kava-kava root, available from Drinks That Work Ltd., Santa Cruz, Calif., was added to 2.5 liters of hot water containing 250 g of hydroxypropyl beta cyclodextrin (Trappsol manufactured by Cyclodextrin Development Inc, Gainesville, Fla.) at 70.degree. C. The mixture was stirred at 80.degree. C. for 10 minutes and the supernatant was separated from the pulverized kava root residue under suction filtration. The kava-kava root residue was extracted with another 2.5 liters of hot water containing 250 g of hydroxypropyl beta cyclodextrin (Trappsol) under the same conditions of the previous extraction. After suction filtration, the two supernatants were combined and then filtered through Celite bed filter paper under vacuum to yield 4.9 liters of a clear yellow solution.

Detailed Description Text (30):

200 g of pulverized dry kava-kava root, available from Drinks That Work Ltd., located in Santa Cruz, Calif., was added to 2.5 liters hot water containing 25 g of beta cyclodextrin (Trappsol) (manufactured by Cyclodextrin Development Inc, Gainesville Fla.) at 70.degree. C. The mixture was stirred at 80.degree. C. for 10 minutes and the supernatant separated from the pulverized kava root residue under suction filtration. The kava-kava root residue was extracted with another 2.5 liters of hot water containing 25 g of beta cyclodextrin (Trappsol) under the same conditions of the previous extraction. After suction filtration, the two supernatants were combined and then filtered through Celite bed filter paper filter under vacuum to yield 4.9 liters of a clear yellow solution.

Detailed Description Text (32):

The kava-kava lactone content of each of the solutions obtained from Examples 7 and 8 was determined by adding about 100 ml of water to the solution to bring its total volume to about 5.0 liters. A 0.5 ml aliquot from each solution was mixed with 0.5 ml EtOH and centrifuged (Centrifuge 5415C, manufactured by Eppendorf) with 1.4.times.1000 min.sup.-1 for 5 minutes. After centrifugation, the supernatant was filtered through a 0.45  $\mu$ m microfilter and a 5  $\mu$ l aliquot of the filtered solution was injected into HPLC.

Detailed Description Text (33):

The kava-kava lactone-containing solution obtained from Example 7 contained kava-kava lactones at concentration of 10 mg/ml. The kava-kava lactone-containing solution obtained from Example 8 contained kava-kava lactones at concentration of 2.0 mg/ml.

Other Reference Publication (1):

Amdidouche-Hussain et al., "Selection of Kavalactones by Complexation of Kava Extract with Cyclodextrins", Drug Development and Industrial Pharmacy 23:1223-1226, 1997.

## CLAIMS:

1. A method of obtaining a kava-kava lactone-containing product comprising heating pulverized kava roots in an aqueous solution including a cyclodextrin-based solubilizing agent to extract kava-kava lactones from the pulverized kava roots.

6. The method of claim 1, wherein the pulverized kava root in the aqueous solution is heated to about 50 to about 90.degree. C.

12. The method of claim 9, wherein the pulverized kava root in an aqueous solution is heated to about 50.degree. C. to about 90.degree..

13. A method of obtaining a kava-kava lactone-containing product, the method comprising:

heating a crude kava-kava lactone-containing preparation in an aqueous solution including a cyclodextrin-based solubilizing agent to solubilize kava-kava lactones in the crude preparation and thereby produce an aqueous kava-kava lactone-containing solution; and

removing flavokawains from the kava-kava lactone-containing solution.

17. The method of claim 13, wherein the crude kava-kava lactone-containing preparation in an aqueous solution is heated to about 50 to about 90.degree. C.

22. The method of claim 20, wherein the crude kava-kava lactone-containing preparation in an aqueous solution is heated to about 50 to about 90.degree. C.

23. The method of claim 13, wherein the flavokawains are removed by filtering the kava-kava lactone-containing solution.

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)



[First Hit](#) [Fwd Refs](#)[Previous Doc](#)[Next Doc](#)[Go to Doc#](#)

Generate Collection

Print

L3: Entry 16 of 19

File: USPT

Oct 16, 2001

DOCUMENT-IDENTIFIER: US 6303157 B1

TITLE: Extracts of kava-kavaAbstract Text (1):

This invention relates to a kava-kava lactone-containing product. Also disclosed is a method of preparing such a kava-kava lactone-containing product by extracting kava-kava lactones from crude kava-kava extracts with a solubilizing agent.

Assignee Name (1):Kava Pharmaceuticals, Inc.Assignee Group (1):Kava Pharmaceuticals, Inc. DE 02Brief Summary Text (2):

The plant kava-kava (piper methysticum Forst. Piperaceae) is native to Polynesia. An intoxicating beverage made from its crushed roots has been used in ceremonies since ancient times.

Brief Summary Text (3):

Kava-kava has been found to have significant analgesic and anesthetic effects via non-opiate pathways. It also can be used as phytotranquilizer to reduce nervousness and overexcitement. However, kava-kava's most popular application is as a natural anxiolytic and has compared favorably to a number prescription medications such as benzodiazepines. Kava-kava's pharmacological activity has been attributed to lactones present in the plant roots.

Brief Summary Text (4):

Several kava-kava products are available, such as kava-kava-based beverages, kava-kava ethanol extract solutions, kava-kava emulsions with glycerin and coconuts oil dispersed in water, and kava-kava extract tablets. Unfortunately, the active lactones in kava-kava-based products have low bioavailability since the lactones themselves are practically insoluble in water. For example, the maximum solubility of kawain at 21.degree. C. is about 2.2 mg/100 ml water. Accordingly, high doses of kava-kava-based products or the active lactones are required to obtain therapeutic effects.

Brief Summary Text (6):

In one aspect, the invention features a method of obtaining a kava-kava lactone-containing product by heating pulverized kava roots in an aqueous solution which contains a cyclodextrin-based solubilizing agent to extract kava-kava lactones from the pulverized kava-kava roots.

Brief Summary Text (7):

In another aspect, the kava-kava lactone-containing product in dried form includes greater than about 50 parts by weight (e.g., about 50 to about 99 parts by weight) of one or more of the active kava-kava lactones and has a solubility of at least about 0.05 mg/ml (e.g., about 0.05 mg/ml to about 25 mg/ml), preferably greater than about 0.1 mg/ml, and most preferably greater than about 1 mg/ml in water at about 25.degree. C.

Brief Summary Text (9):

In another aspect, the invention features a method of removing flavokawains from a crude kava-kava lactone-containing preparation. The method includes heating the crude kava-kava lactone-containing preparation in an aqueous solution which contains a cyclodextrin-based solubilizing agent to solubilize kava-kava lactones and thereby produce an aqueous kava-kava lactone-containing solution; and removing flavokawains from the solution, such as by filtering. Crude kava-kava lactone-containing preparations, typically, are produced by extracting pulverized kava-kava root with an organic solvent and are commercially available as kava-kava extracts.

Brief Summary Text (10):

In yet another aspect, the invention features a solubilized kava-kava root extract in aqueous form including active kava-kava lactones in a concentration greater than 0.05, preferably greater than about 0.1, and most preferably greater than about 1 weight percent of the extract, and flavokawains in a concentration of less than about 0.3 weight percent of the extract.

Brief Summary Text (11):

In still another aspect, the invention features a solubilized kava-kava root extract in dried form including active kava-kava lactones in a concentration greater than about 50 weight percent of the extract, and flavokawains in a concentration of less than about 0.3 weight percent of extract.

Brief Summary Text (12):

The kava-kava lactone-containing product (i.e., kava-kava root extract) of this invention exhibits desirable composition and performance. It has a high content of kava-kava lactones and a low content of flavokawains, and increased bioavailability and skin permeability of kava-kava lactones when used as an ingredient in a food, pharmaceutical, or cosmetic product.

Drawing Description Text (2):

FIG. 1 shows the HPLC spectrum recorded at 254 nm of the major components in a kava-kava lactone-containing product of this invention.

Detailed Description Text (2):

The present invention relates to a kava-kava lactone-containing product which contains one or more active kava-kava lactones complexed with cyclodextrin-based solubilizing agents. The water solubility of active kava-kava lactones complexed with cyclodextrin can be increased by a factor of about 20 relative to the water solubility of the active kava-kava lactones not complexed with the cyclodextrin-based solubilizing agent. The increased water solubility improves the physiological absorption of active kava-kava lactones into the body.

Detailed Description Text (3):

The active lactones in kava-kava are kawain, dihydrokawain, methysticin, dihydromethysticin, yangonin and desmethoxyyangonin, i.e. 6-substituted 4-methoxypryones of the formulae: ##STR1##

Detailed Description Text (5):

The present invention also relates to a kava-kava lactone-containing product which has reduced amounts of flavokawains of the formula: ##STR2##

Detailed Description Text (6):

Flavokawains are flavone derivatives of the kava-kava active lactone kawain, shown above, and induce undesirable secondary effects such as a scaly skin rash called "Kava dermatopathy" when crude kava-kava lactone-containing preparations (e.g., crude kava-kava extracts) are consumed for long-terms or in large amounts. Crude kava-kava lactone-containing preparations, typically, are produced by extracting kava-kava lactones from pulverized kava-kava root with an organic solvent, such as

ethanol (ETOH), which also co-extracts flavokawains along with the desired lactones. The kava-kava lactone-containing product of this invention can be taken orally or applied to the skin. In dried form (e.g., a dry solubilized kava-kava root extract), it includes greater than about 50 parts by weight of one or more of the kava-kava lactones and less than about 0.3 weight percent of flavokawains, and has a solubility greater than about 0.05 mg/ml preferably greater than about 0.1 mg/ml, and most preferably greater than about 1 mg/ml in water at about 25.degree. C. The kava-kava lactone-containing product, in aqueous form (e.g., an aqueous solubilized kava-kava root extract), includes less than about 0.3 weight percent of flavokawains and kava-kava lactones in a concentration greater than about 0.05, preferably greater than about 0.1, and most preferably greater than about 1 weight percent of the extract. Unexpectedly the method of this invention enables one to extract directly the kava-kava lactones from kava-kava roots without using organic solvents by complexing the kava-kava lactones with a solubilizing agent, e.g., a cyclodextrin-based solubilizing agent.

Detailed Description Text (10):

The method of preparing a kava-kava lactone-containing product includes mixing between about 1 and about 20 parts by weight of a crude kava-kava extract or pulverized kava-kava root with about 100 parts by weight of a solution heated to between about 30.degree. C. and about 70.degree. C. of water containing about 0.01 to about 25 percent by weight, and preferably about 0.1 to about 15 percent by weight of the cyclodextrin-based solubilizing agent relative to the total weight of the aqueous solution. The resulting mixture is heated to about 50.degree. C. to about 90.degree. C. and stirred for about 1 to about 10 minutes. While stirring, the mixture is cooled to about 30.degree. C. to about 50.degree. C. for between about 1 and about 10 minutes. The supernatant contains water-soluble complexes of active kava-kava lactones and cyclodextrin-based solubilizing agents.

Detailed Description Text (11):

Unexpectedly, cyclodextrin-based solubilizing agents have relatively weak affinity for forming a water-soluble complex with flavokawains as compared to kava-kava lactones. As a result most of the flavokawains in the kava-kava crude extract or pulverized kava-kava root are not solubilized into the supernatant. Residual amounts of flavokawains in the supernatant, e.g., about 3% to about 0.5%, give rise to a yellow color of the supernatant and can be removed by microfiltering the supernatant. The microfiltered supernatant is colorless and substantially flavokawain-free. Any microfilter having a pore size sufficient to remove residual flavokawain (e.g., 1 .mu.m) can be used. In alternative embodiments, residual amounts of flavokawains in the supernatant can be removed by cold precipitation or solvent distribution.

Detailed Description Text (12):

The kava-kava lactone-containing product of this invention can be produced by a batch method or a flow method, i.e., a continuous extraction and filtration process. Typically, flow processes are used to help maintain reasonable manufacturing costs. The kava-kava lactone-containing product in aqueous form can be dried, (e.g., under vacuum) to produce a dried product. The kava-kava lactone-containing product, either in dried or aqueous form, can be incorporated into an edible composition, pharmaceutical composition, a cosmetic product, or a skin care product. The edible composition can be a solid, a paste, or a liquid food product, such as water, milk, tea, coffee, soft drinks, juices, beer, seasonings, cereals, cookies, chewing gum, chocolate, or soups.

Detailed Description Text (15):

50 g of a crude kava-kava extract containing about 7.5 g of kava-kava lactones and about 3 weight percent flavokawains. (i.e., alcohol free KAVA-KAVA root suspension manufactured by Nature Answer Inc., Hauppauge, N.Y.) was added to 3 liters of hot water containing 200 g of hydroxypropyl beta cyclodextrin (Trappsol manufactured by Cyclodextrin Development Inc, Gainesville, Fla.) at 70.degree. C. The mixture was

stirred at 90.degree. C. for 10 minutes and then at 50.degree. C. for an additional 10 minutes. The supernatant was filtered through a 1 .mu.m-pore size microfilter to yield 3.3 liters of a visibly colorless and clear water-soluble kava-kava lactone-containing solution. The kava-kava lactone content of the solution was about 1.6 mg/ml. The concentration of flavokawains was less than about 0.3 weight percent.

Detailed Description Text (17):

50 g of a crude kava-kava extract containing about 7.5 g of kava-kava lactones extracted with EtOH and about 3 weight percent flavokawains ( i.e., KAVA-KAVA Root GBE ethanol solution manufactured by GAIA Herbs Inc, Brevard, N.C.) was added to 3 liters of hot water containing 300 g of hydroxypropyl beta cyclodextrin (Encapsin HPB manufactured by American Maize-Products Company, Hammond, Id.) at 70.degree. C. The mixture was stirred at 90.degree. C. for 10 minutes. Residual EtOH was removed from the mixture by evaporation under vacuum at 30.degree. C. The supernatant was filtered through a 1 .mu.m-pore size microfilter to yield 3.2 liters of a visibly colorless and clear water-soluble (alcohol-free) kava-kava lactone-containing solution. The kava-kava lactone content of the solution was about 2.0 mg/ml. The concentration of flavokawains was less than about 0.3 weight percent.

Detailed Description Text (19):

50 g of a crude kava-kava extract containing about 7.5 g of kava-kava lactones and about 3 weight percent flavokawains (i.e., KAVA-KAVA Root GBE ethanol solution manufactured by GAIA Herbs Inc, Brevard, N.C.) was added to 3 liters of hot water containing 20 g of .beta.-cyclodextrin (C\*Cavitron 82800, food grade, manufactured by Cerester USA Inc in Hammon, Ind. The mixture was stirred at 90.degree. C. for 10 minutes and then at 50.degree. C. for an additional 10 minutes. The supernatant was filtered through a 1 .mu.m-pore size microfilter to yield 3.0 liters of a visibly colorless and clear water-soluble kava-kava lactone-containing solution. The kava-kava lactone content of the solution was about 0.25 mg/ml. The concentration of flavokawains was less than about 0.3 weight percent.

Detailed Description Text (21):

50 g of a crude kava-kava extract containing about 5 g of kava-kava lactones extracted with EtOH and about 3 weight percent flavokawains (i.e., KAVA-KAVA Root GBE ethanol solution manufactured by GAIA Herbs Inc, Brevard, N.C.) was added to 3 liters of hot water containing 20 g of cyclodextrin and 150 g of hydroxypropyl beta cyclodextrin at 70.degree. C. The mixture was stirred at 90.degree. C. for 10 minutes and then at 50.degree. C. for an additional 10 minutes. The supernatant was filtered through a 1 .mu.m-pore size microfilter to yield 2.8 liters a visibly colorless and clear water-soluble kava-kava lactone-containing solution. The kava-kava lactone content of the solution was about 1.2 mg/ml. The concentration of flavokawains was less than about 0.3 weight percent.

Detailed Description Text (23):

A crude kava-kava extract containing 75 mg kava-kava lactones per 1 ml ethanol and about 3 weight percent flavokawains (KAVA-KAVA Root GBE manufactured by GAIA Herbs Inc, Brevard, N.C.) was used to prepare a reference standard for high-pressure liquid chromatography (HPLC) measurements. More specifically, 1 ml of the standardized kava-kava extract was added to 9 ml of water containing 1 g of hydroxypropyl beta cyclodextrin (USP grade) at 50.degree. C. The mixture was stirred for 5 minutes to yield a standardized kava-kava extract solution (yellowish). An HPLC sample was prepared by diluting it with 5.times. of 80% EtOH. The concentration of flavokawains in the sample was about 3 weight percent.

Detailed Description Text (24):

HPLC spectra were recorded on a HP 1050 instrument (Hewlet Packard) using a C18-reverse phase column 150 mm.times.4.6 mm, Symmetry Shield RP18 available from (Waters) by a gradient elution method, i.e., 1 ml/min for 20 minutes with 20%-95% aqueous acetonitrile and 0.1% trifluoroacetic acid at 30.degree. C. The HPLC detector was set at either 254 nm or 330 nm. FIG. 1 shows the HPLC spectrum of the

standardized kava-kava extract solution recorded by monitoring the absorption at 254 nm as a function of time. FIG. 2 shows a HPLC spectrum of the standardized kava-kava extract solution recorded by monitoring the absorption at 330 nm as a function of time. The six kava-kava lactones appear in the HPLC spectra of FIGS. 1 and 2 as overlapping peaks (FIG. 3) Note that the intensity of each absorbance is not directly related to the relative amounts of kava lactones in the standardized Kava extract because each lactone has a different absorption maxima ( $\lambda_{max}$ ) value and extinction coefficient.

Detailed Description Text (26):

Flavokawains have a maximum absorption around about 340 nm and are responsible for the yellow color of the standardized kava-kava extract solution. The flavokawian's (i.e., the yellowish color) in the HPLC sample of Example 5 were removed from the solution by filtering it with through a 0.45  $\mu$ m microfilter. The concentration of flavokawains in the filtered HPLC sample was less than about 0.3 weight percent.

Detailed Description Text (28):

200 g of pulverized dry kava-kava root, available from Drinks That Work Ltd., Santa Cruz, Calif., was added to 2.5 liters of hot water containing 250 g of hydroxypropyl beta cyclodextrin (Trappsol manufactured by Cyclodextrin Development Inc, Gainesville, Fla.) at 70.degree. C. The mixture was stirred at 80.degree. C. for 10 minutes and the supernatant was separated from the pulverized kava root residue under suction filtration. The kava-kava root residue was extracted with another 2.5 liters of hot water containing 250 g of hydroxypropyl beta cyclodextrin (Trappsol) under the same conditions of the previous extraction. After suction filtration, the two supernatants were combined and then filtered through Celite bed filter paper under vacuum to yield 4.9 liters of a clear yellow solution.

Detailed Description Text (30):

200 g of pulverized dry kava-kava root, available from Drinks That Work Ltd., located in Santa Cruz, Calif., was added to 2.5 liters hot water containing 25 g of beta cyclodextrin (Trappsol) (manufactured by Cyclodextrin Development Inc, Gainesville Fla.) at 70.degree. C. The mixture was stirred at 80.degree. C. for 10 minutes and the supernatant separated from the pulverized kava root residue under suction filtration. The kava-kava root residue was extracted with another 2.5 liters of hot water containing 25 g of beta cyclodextrin (Trappsol) under the same conditions of the previous extraction. After suction filtration, the two supernatants were combined and then filtered through Celite bed filter paper filter under vacuum to yield 4.9 liters of a clear yellow solution.

Detailed Description Text (32):

The kava-kava lactone content of each of the solutions obtained from Examples 7 and 8 was determined by adding about 100 ml of water to the solution to bring its total volume to about 5.0 liters. A 0.5 ml aliquot from each solution was mixed with 0.5 ml EtOH and centrifuged (Centrifuge 5415C, manufactured by Eppendorf) with 1.4.times.1000 min.sup.-1 for 5 minutes. After centrifugation, the supernatant was filtered through a 0.45  $\mu$ m microfilter and a 5  $\mu$ l aliquot of the filtered solution was injected into HPLC.

Detailed Description Text (33):

The kava-kava lactone-containing solution obtained from Example 7 contained kava-kava lactones at concentration of 10 mg/ml. The kava-kava lactone-containing solution obtained from Example 8 contained kava-kava lactones at concentration of 2.0 mg/ml.

Other Reference Publication (1):

Amdidouche-Hussain et al., "Selection of Kavalactones by Complexation of Kava Extract with Cyclodextrins", Drug Development and Industrial Pharmacy 23:1223-1226, 1997.

## CLAIMS:

1. A method of obtaining a kava-kava lactone-containing product comprising heating pulverized kava roots in an aqueous solution including a cyclodextrin-based solubilizing agent to extract kava-kava lactones from the pulverized kava roots.

6. The method of claim 1, wherein the pulverized kava root in the aqueous solution is heated to about 50 to about 90.degree. C.

12. The method of claim 9, wherein the pulverized kava root in an aqueous solution is heated to about 50.degree. C. to about 90.degree..

13. A method of obtaining a kava-kava lactone-containing product, the method comprising:

heating a crude kava-kava lactone-containing preparation in an aqueous solution including a cyclodextrin-based solubilizing agent to solubilize kava-kava lactones in the crude preparation and thereby produce an aqueous kava-kava lactone-containing solution; and

removing flavokawains from the kava-kava lactone-containing solution.

17. The method of claim 13, wherein the crude kava-kava lactone-containing preparation in an aqueous solution is heated to about 50 to about 90.degree. C.

22. The method of claim 20, wherein the crude kava-kava lactone-containing preparation in an aqueous solution is heated to about 50 to about 90.degree. C.

23. The method of claim 13, wherein the flavokawains are removed by filtering the kava-kava lactone-containing solution.

[Previous Doc](#)

[Next Doc](#)

[Go to Doc#](#)



SCIENCE @ DIRECT

Register or Login:

Password: [Home](#)[Search](#)[Journals](#)[Abstract Databases](#)[Books](#)[Reference Works](#)[My Profile](#)[Alerts](#)Quick Search: 

within

[? Search Tips](#)[previous page](#)

results 1 - 5

[next page](#)

## 5 Articles Found

kava and methysticum and beer

[Edit Search](#) | [Save Search](#) | [Save as Search Alert](#) [Search With](#)[display checked docs](#)[e-mail articles](#)[export citations](#)

View:

Sort By:

1. ☐ **The chick separation stress paradigm: a validation study** • ARTICLE  
*Pharmacology Biochemistry and Behavior, Volume 77, Issue 2, February 2004, Pages 221-226*  
Matt W. Feltenstein, Jason E. Warnick, Amanda N. Guth and Kenneth J. Sufka  
[SummaryPlus](#) | [Full Text + Links](#) | [PDF \(156 K\)](#)
2. ☐ **Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties** • REVIEW ARTICLE  
*Free Radical Biology and Medicine, Volume 37, Issue 3, 1 August 2004, Pages 287-303*  
Giuseppe Galati and Peter J. O'Brien  
[SummaryPlus](#) | [Full Text + Links](#) | [PDF \(430 K\)](#)
3. ☐ **"Bust enhancing" herbal products** • SHORT COMMUNICATION  
*Obstetrics & Gynecology, Volume 101, Issue 6, June 2003, Pages 1345-1349*  
Adriane Fugh-Berman  
[Abstract](#)
4. ☐ **Kava: an overview** • REVIEW ARTICLE  
*Journal of Ethnopharmacology, Volume 37, Issue 1, August 1992, Pages 13-45*  
Yadhu N. Singh  
[Abstract](#)
5. ☐ **Kava, alcohol and tobacco consumption among Tongans with urbanization** • ARTICLE  
*Social Science & Medicine, Volume 16, Issue 1, 1982, Pages 35-41*  
Sitaleki A. Finau, John M. Stanhope and Ian A. M. Prior  
[Abstract](#)

## 5 Articles Found

kava and methysticum and beer

[Edit Search](#) | [Save Search](#) | [Save as Search Alert](#)[previous page](#)

results 1 - 5

[next page](#)[Home](#)[Search](#)[Journals](#)[Abstract Databases](#)[Books](#)[Reference Works](#)[My Profile](#)[Alerts](#)

[Feedback](#) | [Terms & Conditions](#) | [Privacy Policy](#)

Copyright © 2004 [Elsevier B.V.](#) All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.





SCIENCE @ DIRECT

Register or Login:

user name

Password:

Go

Home

Search

Journals

Abstract Databases

Books

Reference Works

My Profile

Alerts

Quick Search:

within

All Full-text Sources

Go

Search Tips

Previous Page

results 1 - 5

Next Page

## 5 Articles Found

kava and methysticum and beer

[Edit Search](#) | [Save Search](#) | [Save as Search Alert](#)[Search With](#)[display checked docs](#)[e-mail articles](#)[export citations](#)

View: Citations

Sort By: Date

1. ☐ **The chick separation stress paradigm: a validation study • ARTICLE**  
*Pharmacology Biochemistry and Behavior, Volume 77, Issue 2, February 2004, Pages 221-226*  
Matt W. Feltenstein, Jason E. Warnick, Amanda N. Guth and Kenneth J. Sufka  
[SummaryPlus](#) | [Full Text + Links](#) | [PDF \(156 K\)](#)
2. ☐ **Potential toxicity of flavonoids and other dietary phenolics: significance for their chemopreventive and anticancer properties • REVIEW ARTICLE**  
*Free Radical Biology and Medicine, Volume 37, Issue 3, 1 August 2004, Pages 287-303*  
Giuseppe Galati and Peter J. O'Brien  
[SummaryPlus](#) | [Full Text + Links](#) | [PDF \(430 K\)](#)
3. ☐ **"Bust enhancing" herbal products • SHORT COMMUNICATION**  
*Obstetrics & Gynecology, Volume 101, Issue 6, June 2003, Pages 1345-1349*  
Adriane Fugh-Berman  
[Abstract](#)
4. ☐ **Kava: an overview • REVIEW ARTICLE**  
*Journal of Ethnopharmacology, Volume 37, Issue 1, August 1992, Pages 13-45*  
Yadhu N. Singh  
[Abstract](#)
5. ☐ **Kava, alcohol and tobacco consumption among Tongans with urbanization • ARTICLE**  
*Social Science & Medicine, Volume 16, Issue 1, 1982, Pages 35-41*  
Sitaleki A. Finau, John M. Stanhope and Ian A. M. Prior  
[Abstract](#)

## 5 Articles Found

kava and methysticum and beer

[Edit Search](#) | [Save Search](#) | [Save as Search Alert](#)

Previous Page

results 1 - 5

Next Page

Home

Search

Journals

Abstract Databases

Books

Reference Works

My Profile

Alerts

[Feedback](#) | [Terms & Conditions](#) | [Privacy Policy](#)

Copyright © 2004 [Elsevier B.V.](#) All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.